ERα-XPO1 Cross Talk Controls Tamoxifen Sensitivity in Tumors by Altering ERK5 Cellular Localization.

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Recurrent, estrogen receptor-positive (ERα(+)), metastatic breast cancer poses a significant threat, necessitating novel therapeutic strategies.
• Endocrine therapies like tamoxifen are crucial but can fail due to acquired resistance.
• Identifying biomarkers for endocrine therapy failure and developing methods to overcome resistance are critical unmet needs.

Purpose of the Study:

• To validate nuclear transport genes, including XPO1, as biomarkers for predicting endocrine therapy failure in ERα(+) breast cancer.
• To investigate the role of XPO1 in tamoxifen resistance.
• To evaluate the efficacy of inhibiting XPO1 as a strategy to resensitize resistant tumors to endocrine therapy.

Main Methods:

• Analysis of human breast cancer gene expression data sets using advanced statistical methods to correlate nuclear transport gene expression with survival and recurrence.
• Mechanistic studies in tamoxifen-resistant cell lines and tumor xenografts to assess the impact of XPO1 expression on signaling pathways and tamoxifen response.
• In vivo evaluation of combined treatment with a XPO1 inhibitor (Selinexor) and tamoxifen.

Main Results:

• Elevated expression of nuclear transport genes, including XPO1, was associated with poor survival and predicted tamoxifen resistance in ERα(+) breast tumors.
• XPO1 expression levels influenced the cellular localization of key signaling proteins and determined the response to tamoxifen.
• Combined inhibition of XPO1 (using Selinexor) and ERα with tamoxifen restored tamoxifen sensitivity in resistant models and prevented tumor recurrence in vivo.

Conclusions:

• Nuclear transport pathways, particularly XPO1, are newly implicated in the development of endocrine resistance in ERα(+) breast cancer.
• XPO1 inhibition represents a promising therapeutic strategy to overcome tamoxifen resistance.
• These findings offer potential for improved patient selection for endocrine therapy and enhanced treatment outcomes for relapsed ERα(+) breast cancer, reducing cancer recurrence.